FDA
FDA Articles
Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.
Published:
Last Updated:
Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne muscular dystrophy.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Published:
Last Updated:
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.
Published:
Last Updated:
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Published:
Last Updated:
Clovis Oncology shares saw a massive gain on Tuesday, on the heels of news that the FDA had granted it a priority review of its cancer drug.
Published:
Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares climb late Tuesday after the company announced a key U.S. Food and Drug Administration (FDA) approval. Note that this is the first of a few...
Published:
Last Updated:
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
Published:
Last Updated:
Theranos CEO Elizabeth Holmes presented a new blood test system as a means to diversify beyond its earlier, failed products, but many scientists who saw the presentation thought it was a weak...
Published:
Last Updated:
Puma Biotechnology watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial.
Published:
Last Updated:
Shares of Progenics Pharmaceuticals and Valeant Pharmaceuticals made handy gains in the market on Wednesday following a key FDA approval that could be a real turning point for the companies.
Published:
Last Updated:
Investor reaction to Synergy Pharmaceuticals reaching the FDA mid-cycle review milestone for the plecanatide new drug application in chronic idiopathic constipation was not as positive as the company...
Published:
Last Updated:
CytRx absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results.
Published:
Last Updated: